Narrower focus will pay off for Baxter

Medical device maker Baxter International aims to improve shareholder value with new plan to simplify its operations.
Under that plan, it’s selling its BioPharma Solutions business, whose products and services help drugmakers manufacture their products. Baxter also plans to spin off its Renal Care and Acute… Read More

Expect continuing gains from Baxter International

Expect continuing gains from Baxter International

Improved sales following an acquisition led to a 20.9% jump in revenue for this company during the most-recent quarter.

The medical device maker continues to enjoy strong demand for its products as hospitals and clinics resume regular procedures on easing of COVID-19 lockdowns and other restrictions… Read More

Three buys for post-pandemic returns

These three medical device makers continue to enjoy strong demand for their products as hospitals and clinics resume regular procedures on easing of COVID-19 lockdowns and other restrictions. While ongoing supply-chain problems add risk, we like their long-term prospects.
BAXTER INTERNATIONAL INC. $56 is a buy. The… Read More

Earnings rose 8.8% at Baxter International

Earnings rose 8.8% at Baxter International

The firm’s shares are down since April 2020, largely because hospitals postponed elective surgical procedures due to the COVID-19 pandemic. 

But now the pandemic is easing and demand for this firm’s products is rebounding. The company’s purchase of a hospital equipment maker should also position it… Read More

This acquisition is already paying off

BAXTER INTERNATIONAL INC. $75 is a buy. The company (New York symbol BAX; Conservative Growth Portfolio, Manufacturing & Industry sector; Shares outstanding: 503.5 million; Market cap: $37.8 billion; Price-to-sales ratio: 2.7; Dividend yield: 1.5%; TSINetwork Rating: Average; www.baxter.com) recently acquired Hill-Rom Holdings Inc. for $12.4 billion. Hill-Rom makes… Read More